KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.
Adil Daud(University of California, San Francisco), Georgina V. Long(The University of Sydney), Erika Richtig(Medical University of Graz), Marcus O. Butler(University of Toronto), Christian Caglevic, Ahmad A. Tarhini(UPMC Hillman Cancer Center), Marta Nyakas(Oslo University Hospital), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Jose Lutzky, Igor Puzanov(Roswell Park Comprehensive Cancer Center), Steven O’Day(Saint John's Health Center), Kenneth Emancipator(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Millward(The University of Western Australia), Kim Margolin(City Of Hope National Medical Center), Christian U. Blank(The Netherlands Cancer Institute), Elaine McWhirter(Juravinski Cancer Centre), Caroline Robert(Institut Gustave Roussy), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 15
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k